Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (XTNT) is a leader in regenerative medicine, specializing in orthobiologics and spinal implant systems for complex surgical procedures. This page aggregates official company news, including product developments, financial updates, and strategic initiatives within the orthopedic and neurological sectors.
Investors and healthcare professionals will find verified press releases covering regulatory milestones, partnership announcements, and advancements in bone healing technologies. Our repository ensures access to timely updates on Xtant Medical's surgical solutions, including spinal fusion devices and biologics designed to improve patient outcomes.
Bookmark this page for direct access to earnings reports, acquisition news, and clinical trial progress. All content is sourced from official channels to maintain accuracy and compliance with financial disclosure standards.
Xtant Medical Holdings, Inc. announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™, for chronic and acute wounds. The products are dehydrated, terminally irradiated, single and dual-layer amniotic membrane sheets intended to provide protective coverage from the surrounding environment when applied topically. Manufactured at Xtant’s biologics processing center in Belgrade, Montana, the company aims to position itself as a leader and innovator in advanced biologic therapies.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
